82150
Amylase; blood
CPT code 82150 refers to the laboratory analysis of amylase levels in the blood. Amylase is a vital digestive enzyme primarily synthesized and secreted by the acinar cells of the pancreas and the salivary glands. Its physiological role is to catalyze the hydrolysis of starch into smaller carbohydrate molecules like maltose. In clinical practice, the measurement of serum amylase is a cornerstone in the evaluation of patients presenting with acute abdominal pain, particularly when acute pancreatitis is suspected. When the pancreas becomes inflamed or injured, amylase leaks into the interstitial space and subsequently into the bloodstream, leading to significant elevations that typically manifest within 2 to 12 hours of symptom onset. The concentration usually peaks at 12 to 72 hours and returns to baseline within 3 to 5 days, provided the underlying inflammation resolves. Beyond the pancreas, amylase is also found in the fallopian tubes, small intestine, and skeletal muscle. Therefore, elevations in 82150 results can also be associated with non-pancreatic conditions such as mumps (salivary gland inflammation), intestinal perforation, mesenteric infarction, or ruptured ectopic pregnancy. The laboratory procedure involves a standard venipuncture to collect a serum or plasma specimen, which is then analyzed using enzymatic or colorimetric assays on automated chemistry platforms. Because amylase is excreted by the kidneys, patients with renal insufficiency may demonstrate chronically elevated levels due to decreased clearance, a factor that must be considered during clinical interpretation.
Clinical Indications
- Diagnosis and monitoring of acute pancreatitis
- Evaluation of chronic pancreatitis exacerbations
- Assessment of salivary gland disorders such as sialadenitis or mumps
- Differential diagnosis of acute abdominal pain
- Monitoring for pancreatic duct obstruction
- Evaluation of potential complications following Endoscopic Retrograde Cholangiopancreatography (ERCP)
- Assessment of suspected intestinal ischemia or perforation
- Investigation of macroamylasemia in asymptomatic patients with elevated levels
Procedure Steps
- Verify the physician order for serum amylase and identify the patient using two identifiers.
- Perform a standard venipuncture to collect a blood sample in a serum separator tube (SST) or lithium heparin tube.
- Invert the collection tube gently to ensure proper mixing with additives or clot activators.
- Allow the specimen to clot if using a serum tube, then centrifuge the sample to separate the serum/plasma from the cellular components.
- Aliquot the serum/plasma into a secondary container if required by laboratory protocol.
- Load the specimen onto an automated chemistry analyzer for quantitative measurement.
- Utilize enzymatic methods (e.g., using p-nitrophenylglycosides as substrates) to determine amylase activity via spectrophotometry.
- Review and validate the results against laboratory reference ranges and quality control standards.
- Electronically transmit or manually record the final result in the patient's medical record.
Coding Guidelines
- Report 82150 for amylase testing performed on blood (serum or plasma) specimens.
- If amylase is measured in a urine specimen, use CPT code 82151 instead of 82150.
- For repeat amylase testing on the same day to monitor a rapidly changing clinical condition, append modifier 91 (Repeat clinical diagnostic laboratory test).
- Amylase is not included in the Basic Metabolic Panel (80047/80048) or the Comprehensive Metabolic Panel (80053) and should be coded separately if performed.
- Medical necessity for 82150 is often tied to specific ICD-10-CM codes; providers should ensure documentation supports the symptoms or diagnosis being investigated.
- If the test is performed as part of a larger, custom laboratory panel, ensure each component is unbundled unless a specific organ or disease-oriented panel code exists that includes amylase (though none currently do in the standard CPT panel sets).